White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment

Alzheimer's and Dementia

Volumn 9, Issue 5 SUPPL., 2013, Pages

  Guzman, Vanessa A ^a   Carmichael, Owen T ^b   Schwarz, Christopher ^c   Tosto, Giuseppe ^a,d   Zimmerman, Molly E ^e   Brickman, Adam M ^a,d  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

amyloid; Alzheimer's disease; Mild cognitive impairment; Tau; White matter hyperintensities

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER HYPERINTENSITY; WHITE MATTER LESION; METABOLISM; MYELINATED NERVE; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PHYSIOLOGY; RECALL; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL RECALL; MILD COGNITIVE IMPAIRMENT; MODELS, STATISTICAL; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84885619924     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.11.009     Document Type: Article

References (41)

1. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
2. T. Tapiola, I. Alafuzoff, S.K. Herukka, L. Parkkinen, P. Hartikainen, and H. Soininen Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 2009 382 389
3. J. Toledo, J. Brettschneider, M. Grossman, S. Arnold, W. Hu, and S. Xie CSF biomarkers cutoffs: the importance of coincident neuropathological diseases Acta Neuropathol 124 2012 23 35
4. C.R. Jack Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Radiology 263 2012 344 361
5. W. Jagust, B. Reed, D. Mungas, W. Ellis, and C. Decarli What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69 2007 871 877
6. S.A. Small, S.A. Schobel, R.B. Buxton, M.P. Witter, and C.A. Barnes A pathophysiological framework of hippocampal dysfunction in ageing and disease Nat Rev Neurosci 12 2011 585 601
7. T.R. Stoub, M. Bulgakova, S. Leurgans, D.A. Bennett, D. Fleischman, and D.A. Turner MRI predictors of risk of incident Alzheimer disease: a longitudinal study Neurology 64 2005 1520 1524
8. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
9. W.M. van der Flier, F. Barkhof, and P. Scheltens Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI Ann NY Acad Sci 1097 2007 215 224
10. A.M. Brickman, J. Muraskin, and M.E. Zimmerman Structural neuroimaging in Alzheimer's disease: do white matter hyperintensities matter? Dialogues Clin Neurosci 11 2009 181 190
11. J.A. Schneider, Z. Arvanitakis, W. Bang, and D.A. Bennett Mixed brain pathologies account for most dementia cases in community-dwelling older persons Neurology 69 2007 2197 2204
12. M. Yoshita, E. Fletcher, D. Harvey, M. Ortega, O. Martinez, and D.M. Mungas Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD Neurology 67 2006 2192 2198
13. Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, et al. Parietal lobe white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer's disease in a community-based cohort. Arch Neurol in press.
14. A.M. Brickman, L.S. Honig, N. Scarmeas, O. Tatarina, L. Sanders, and M.S. Albert Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease Arch Neurol 65 2008 1202 1208
15. L. deToledo-Morrell, T.R. Stoub, M. Bulgakova, R.S. Wilson, D.A. Bennett, and S. Leurgans MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD Neurobiol Aging 25 2004 1197 1203
16. J.C. Morris, M. Storandt, J.P. Miller, D.W. McKeel, J.L. Price, and E.H. Rubin Mild cognitive impairment represents early-stage Alzheimer disease Arch Neurol 58 2001 397 405
17. R.C. Petersen, P.S. Aisen, L.A. Beckett, M.C. Donohue, A.C. Gamst, and D.J. Harvey Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology 74 2010 201 209
18. V.C. Hachinski, L.D. Iliff, E. Zilhka, G.H. Du Boulay, V.L. McAllister, and J. Marshall Cerebral blood flow in dementia Arch Neurol 32 1975 632 637
19. J.A. Yesavage, T.L. Brink, T.L. Rose, O. Lum, V. Huang, and M. Adey Development and validation of a geriatric depression screening scale: a preliminary report J Psychiatr Res 17 1982 37 49
20. C.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, and D. Harvey The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods J Magn Reson Imaging 27 2008 685 691
21. O. Carmichael, J. Xie, E. Fletcher, B. Singh, and C. DeCarli Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume Neurobiol Aging 33 2012 1124.e31 1124.e41
22. C. Schwarz, E. Fletcher, C. DeCarli, and O. Carmichael Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR Inf Process Med Imaging 21 2009 239 251
23. D. Rueckert, L.I. Sonoda, C. Hayes, D.L. Hill, M.O. Leach, and D.J. Hawkes Nonrigid registration using free-form deformations: application to breast MR images IEEE Trans Med Imaging 18 1999 712 721
24. R. Wolz, V. Julkunen, J. Koikkalainen, E. Niskanen, D.P. Zhang, and D. Rueckert Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease PLoS One 6 2011 e25446
25. C. DeCarli, D.G. Murphy, D. Teichberg, G. Campbell, and G.S. Sobering Local histogram correction of MRI spatially dependent image pixel intensity nonuniformity J Magn Reson Imaging 6 1996 519 528
26. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, M. Figurski, E. Coart, and K. Blennow Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI Acta Neuropathol 121 2011 597 609
27. K.A. Welsh-Bohmer, and L.H. Warren Neurodegenerative dementias D.K. Attix, K.A. Welsh-Bohmer, Geriatric neuropsychology: assessment and intervention 2006 Guilford Press New York 56 88
28. A. Levey, J. Lah, F. Goldstein, K. Steenland, and D. Bliwise Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease Clin Ther 28 2006 991 1001
29. J.A. Schneider, Z. Arvanitakis, S.E. Leurgans, and D.A. Bennett The neuropathology of probable Alzheimer disease and mild cognitive impairment Ann Neurol 66 2009 200 208
30. M.E. Murray, N.R. Graff-Radford, O.A. Ross, R.C. Petersen, R. Duara, and D.W. Dickson Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study Lancet Neurol 10 2011 785 796
31. S.K. Herukka, C. Pennanen, H. Soininen, and T. Pirttila CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy J Alzheimers Dis 14 2008 51 57
32. R.S. Desikan, L.K. McEvoy, W.K. Thompson, D. Holland, J.C. Roddey, and K. Blennow Amyloid-beta associated volume loss occurs only in the presence of phospho-tau Ann Neurol 70 2011 657 661
33. E.C. Mormino, J.T. Kluth, C.M. Madison, G.D. Rabinovici, S.L. Baker, and B.L. Miller Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects Brain 132 2009 1310 1323
34. L.G. Apostolova, K.S. Hwang, J.P. Andrawis, A.E. Green, S. Babakchanian, and J.H. Morra 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects Neurobiol Aging 31 2010 1284 1303
35. M.J. de Leon, S. DeSanti, R. Zinkowski, P.D. Mehta, D. Pratico, and S. Segal Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment Neurobiol Aging 27 2006 394 401
36. L.C. de Souza, M. Chupin, F. Lamari, C. Jardel, D. Leclercq, and O. Colliot CSF tau markers are correlated with hippocampal volume in Alzheimer's disease Neurobiol Aging 33 2012 1253 1257
37. H. Hampel, K. Burger, J.C. Pruessner, R. Zinkowski, J. DeBernardis, and D. Kerkman Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease Arch Neurol 62 2005 770 773
38. A.M. Fagan, D. Head, A.R. Shah, D. Marcus, M. Mintun, and J.C. Morris Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly Ann Neurol 65 2009 176 183
39. J.D. Sluimer, F.H. Bouwman, H. Vrenken, M.A. Blankenstein, F. Barkhof, and W.M. van der Flier Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study Neurobiol Aging 31 2010 758 764
40. K. Buerger, M. Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff, and S.J. Teipel CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 2006 3035 3041
41. A.J. Jak, M.W. Bondi, L. Delano-Wood, C. Wierenga, J. Corey-Bloom, and D.P. Salmon Quantification of five neuropsychological approaches to defining mild cognitive impairment Am J Geriatr Psychiatry 17 2009 368 375